<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medvis</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская визуализация</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Visualization</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-0763</issn><issn pub-type="epub">2408-9516</issn><publisher><publisher-name>RDS-Media Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24835/1607-0763-1242</article-id><article-id custom-type="elpub" pub-id-type="custom">medvis-1242</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МАЛЫЙ ТАЗ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SMALL PELVIS</subject></subj-group></article-categories><title-group><article-title>Опыт применения системы VI-RADS в оценке глубины инвазии опухолей мочевого пузыря</article-title><trans-title-group xml:lang="en"><trans-title>Experience in using the VI-RADS system in assessing the depth of invasion of bladder tumors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8784-8415</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каприн</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaprin</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Каприн Андрей Дмитриевич – академик РАН, член-корр. РАО, доктор мед. наук, профессор, генеральный директор, 125284 Москва, 2-й Боткинский пр., д. 3;</p><p>заведующий кафедрой урологии и оперативной нефрологии с курсом онкоурологии медицинского факультета, 117198 Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Andrey D. Kaprin – Full Member of the Russian Academy of Sciences, Corresponding Member of Russian Academy of Education, Doct. of Sci. (Med.), Professor, General Director, 3, 2nd Botkinskiy pr., 125284 Moscow; </p><p>Head of Department of urology and surgical nephrology with a course of oncourology at the medical faculty, 6, Miklukho-Maklay str., Moscow 117198</p></bio><email xlink:type="simple">kaprin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8378-4338</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рубцова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rubtsova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рубцова Наталья Алефтиновна – доктор мед. наук, руководитель отдела лучевой диагностики,</p><p>125284 Москва, 2-й Боткинский пр., д. 3</p></bio><bio xml:lang="en"><p>Natalia A. Rubtsova – Doct. of Sci. (Med.), Head of Radiology Department,</p><p>3, 2nd Botkinskiy pr., 125284 Moscow</p></bio><email xlink:type="simple">rna17@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3550-0139</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кабанов</surname><given-names>Д. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Kabanov</surname><given-names>D. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кабанов Дмитрий Олегович – врач-рентгенолог отделения компьютерной и магнитно-резонансной томографии,</p><p>125284 Москва, 2-й Боткинский пр., д. 3</p></bio><bio xml:lang="en"><p>Dmitry O. Kabanov – radiologist, Department of Оncourology,</p><p>3, 2nd Botkinskiy pr., 125284 Moscow</p></bio><email xlink:type="simple">dkdjap@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4030-3212</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гольбиц</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Golbits</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гольбиц Александра Борисовна – врач-рентгенолог отделения компьютерной и магнитно-резонансной томографии,</p><p>125284 Москва, 2-й Боткинский пр., д. 3</p></bio><bio xml:lang="en"><p>Aleksandra B. Golbits – radiologist, Department of computed tomography and magnetic resonance imaging,</p><p>3, 2nd Botkinskiy pr., 125284 Moscow</p></bio><email xlink:type="simple">a_golbits@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5597-9533</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воробьев</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vorobyev</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Воробьев Николай Владимирович – канд. мед. наук, заведующий отделением онкоурологии, 125284 Москва, 2-й Боткинский пр., д. 3;</p><p>доцент кафедры онкологии, радиотерапии и пластической хирургии, 119991 Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>Nikolai V. Vorobyev – Cand. of Sci. (Med.), Head of Оncourology Department, 3, 2nd Botkinskiy pr., 125284 Moscow;</p><p>Assistant Professor of the Department of Oncology, Radiotherapy and Plastic Surgery, 8, bld. 2, Trubetskaya str., Moscow 119991</p></bio><email xlink:type="simple">dr.vorobyev@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0353-5572</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пильчук</surname><given-names>П. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Pilchuk</surname><given-names>P. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пильчук Павел Сергеевич – врач-онколог отделения онкоурологии,</p><p>125284 Москва, 2-й Боткинский пр., д. 3</p></bio><bio xml:lang="en"><p>Pavel S. Pilchuk – oncologist, Department of computed tomography and magnetic resonance imaging,</p><p>3, 2nd Botkinskiy pr., 125284 Moscow</p></bio><email xlink:type="simple">pilchukdr@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московский научно-исследовательский онкологический институт имени П.А. Герцена – филиал ФГБУ “Национальный медицинский исследовательский центр радиологии” Минздрава России; &#13;
Медицинский институт ФГАОУ ВО “Российский университет дружбы народов” Минобрнауки России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Research Oncological Institute named after P.A. Herzen – branch of “National Medical Research Center of Radiology”, Ministry of Healthcare of Russia; &#13;
Medical institute of the Peoples' Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский научно-исследовательский онкологический институт имени П.А. Герцена – филиал ФГБУ “Национальный медицинский исследовательский центр радиологии” Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Research Oncological Institute named after P.A. Herzen – branch of “National Medical Research Center of Radiology”, Ministry of Healthcare of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Московский научно-исследовательский онкологический институт имени П.А. Герцена – филиал ФГБУ “Национальный медицинский исследовательский центр радиологии” Минздрава России; &#13;
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Research Oncological Institute named after P.A. Herzen – branch of “National Medical Research Center of Radiology”, Ministry of Healthcare of Russia; &#13;
I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>14</day><month>06</month><year>2023</year></pub-date><volume>27</volume><issue>3</issue><fpage>118</fpage><lpage>129</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каприн А.Д., Рубцова Н.А., Кабанов Д.О., Гольбиц А.Б., Воробьев Н.В., Пильчук П.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Каприн А.Д., Рубцова Н.А., Кабанов Д.О., Гольбиц А.Б., Воробьев Н.В., Пильчук П.С.</copyright-holder><copyright-holder xml:lang="en">Kaprin A.D., Rubtsova N.A., Kabanov D.O., Golbits A.B., Vorobyev N.V., Pilchuk P.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medvis.rdsmedia.ru/jour/article/view/1242">https://medvis.rdsmedia.ru/jour/article/view/1242</self-uri><abstract><sec><title>Введение</title><p>Введение. Показатели выживаемости и алгоритмы лечения при раке мочевого пузыря (РМП) зависят от местной распространенности опухоли, в частности от наличия инвазии мышечного слоя МП и экстраорганного роста. Для оценки глубины инвазии РМП в 2018 г. была разработана система VI-RADS, которая основывается на данных мультипараметрической МРТ (мпМРТ). Согласно опубликованным исследованиям, посвященным эффективности применения шкалы VI-RADS, отмечается высокая диагностическая точность для выявления образований с вероятной инвазией в мышечный слой. Вопрос оценки чувствительности и специфичности данной системы в определении экстраорганного опухолевого роста требует дальнейшего изучения.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: оценка диагностической эффективности мпМРТ с применением системы VI-RADS в выявлении мышечной инвазии и экстраорганного роста РМП.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В клиниках ФГБУ “НМИЦ радиологии” проведено проспективное исследование, включающее 75 пациентов в возрасте от 19 до 85 лет, из которых 39 (52%) человек – с впервые выявленным РМП, 36 (48%) – с рецидивом заболевания или продолженным ростом опухоли. Всем больным выполнялась мпМРТ органов малого таза на томографе с индукцией магнитного поля 1,5 Тл с последующим проведением трансуретральной резекции (ТУР), ТУР-биопсии МП или цистэктомии не позднее 6 нед после сканирования. Описание образований МП включало указание их размеров, локализации и оценку по системе VI-RADS. Производилось сопоставление полученных при мпМРТ данных с результатами морфологического исследования с применением статистического анализа.</p></sec><sec><title>Результаты</title><p>Результаты. По результатам проведенной работы общая чувствительность шкалы VI-RADS для категорий выше 3 (наличие мышечной инвазии сомнительно) составила 95,15% [90,11%; 99,95%], выше 4 (вероятная инвазия детрузора) – 92,59% [82,11%; 97,94%], специфичность определялась на уровне 47,62% [25,71%; 70,22%] и 80,95% [58,09%; 94,55%] соответственно. При оценке экстраорганного распространения у 30 пациентов чувствительность составила 83,33% [62,62%; 95,26%], специфичность – 83,33% [35,88%; 99,58%]. Точность и положительная прогностическая значимость также имели высокие значения от 80 до 95%, в отличие от отрицательной прогностической значимости (55,56%).</p></sec><sec><title>Заключение</title><p>Заключение. Шкала оценки глубины инвазии VI-RADS характеризуется высокими показателями чувствительности, специфичности и точности, в том числе в определении экстраорганного распространения при РМП.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Survival rates and treatment algorithms for patients with bladder cancer (BC) depend on the depth of tumor invasion, in particular on the presence of the bladder muscle layer invasion and extraorganic spread. To assess the depth of bladder invasion, the VI-RADS system was developed in 2018, which is based on multiparametric MRI (mpMRI). According to published studies on the VI-RADS effectiveness, there is a high diagnostic accuracy for identifying formations with probable invasion into the muscle layer. The data on BC extraorganic spread are limited and the issue of assessing the sensitivity and specificity of this system requires further study.</p></sec><sec><title>Aim of the study</title><p>Aim of the study. To evaluate the diagnostic performance of mpMRI using the VI-RADS system in detecting muscle invasion and BC extraorganic growth.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A prospective study was conducted in the clinics of the National Medical Research Radiological Centre and included 75 patients aged 19 to 85 years, of which 39 (52%) had been newly diagnosed with BC, 36 (48%) had a relapse or continuous tumor growth. All patients underwent pelvic organs mpMRI on a tomograph with a magnetic field induction of 1.5T, followed by transurethral resection (TUR), TUR-biopsy of the bladder or cystectomy no later than 6 weeks after scanning.. The description of the bladder tumor included its measurements, localization and VI-RADS scale assessment. The data obtained by mpMRI were compared with the results of the morphological study using statistical analysis.</p></sec><sec><title>Results</title><p>Results. According to the results of the study, the overall VI-RADS scale sensitivity for categories above 3 (the presence of muscle invasion is equivocal) was 95.15% [90.11%; 99.95%], above 4 (muscle invasion is likely) – 92.59% [82.11%; 97.94%], specificity was determined at the level of 47.62% [25.71%; 70.22%] and 80.95% [58.09%; 94.55%] respectively. When assessing extraorganic spread in 30 patients, the sensitivity was 83.33% [62.62%; 95.26%], specificity – 83.33% [35.88%; 99.58%]. The accuracy and positive predictive value also had high levels from 80 to 95%, in contrast to the negative predictive value (55.56%).</p></sec><sec><title>Conclusion</title><p>Conclusion. The scale for BC invasion depth assessing VI-RADS is characterized by high rates of sensitivity, specificity and accuracy, in particular when used in determining extraorganic spread.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>МРТ</kwd><kwd>рак мочевого пузыря</kwd><kwd>VI-RADS</kwd></kwd-group><kwd-group xml:lang="en"><kwd>MRI</kwd><kwd>bladder cancer</kwd><kwd>VI-RADS</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Рак мочевого пузыря, 2020. Российские клинические рекомендации (Общероссийский национальный союз “Ассоциация онкологов России”, Общероссийская общественная организация “Российское общество онкоурологов”, Общероссийская общественная организация “Российское общество клинической онкологии”, Общероссийская общественная организация “Российское общество урологов”).</mixed-citation><mixed-citation xml:lang="en">Bladder cancer, 2020. Russian clinical guidelines (Russian National Union “Association of Oncologists of Russia”, Russian Public Organization “Russian Society of Urological Oncology”, Russian Public Organization “Russian Society of Clinical Oncology”, Russian Public Organization “Russian Society of Urologists”) (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">IARC, Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2021.</mixed-citation><mixed-citation xml:lang="en">IARC, Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2021.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2021 году / Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ “НМИЦ радиологии” Минздрава России, 2021. 239 c.</mixed-citation><mixed-citation xml:lang="en">The state of cancer care in Russia in 2020 / Eds Каprin А.D., Starinskiy V.V., Shakhzadova A.O. М.: Moscow Research Oncological Institute named after P.A. Herzen, 2021. 239 p. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Burger M., Catto J.W., Dalbagni G. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 2013; 63 (2): 234–241. https://doi.org/10.1016/j.eururo.2012.07.033</mixed-citation><mixed-citation xml:lang="en">Burger M., Catto J.W., Dalbagni G. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 2013; 63 (2): 234–241. https://doi.org/10.1016/j.eururo.2012.07.033</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Stenzl A., Cowan N.C., European Association of Urology (EAU) et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol. 2011; 59 (6): 1009–1018. https://doi.org/10.1016/j.eururo.2011.03.023</mixed-citation><mixed-citation xml:lang="en">Stenzl A., Cowan N.C., European Association of Urology (EAU) et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol. 2011; 59 (6): 1009–1018. https://doi.org/10.1016/j.eururo.2011.03.023</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kamat A.M., Sylvester R.J., Böhle A. et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J. Clin. Oncol. 2016; 34 (16): 1935–1944. https://doi.org/10.1200/JCO.2015.64.4070</mixed-citation><mixed-citation xml:lang="en">Kamat A.M., Sylvester R.J., Böhle A. et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J. Clin. Oncol. 2016; 34 (16): 1935–1944. https://doi.org/10.1200/JCO.2015.64.4070</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Stein J.P., Lieskovsky G., Cote R. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 2001; 19 (3): 666–675. https://doi.org/10.1200/JCO.2001.19.3.666</mixed-citation><mixed-citation xml:lang="en">Stein J.P., Lieskovsky G., Cote R. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 2001; 19 (3): 666–675. https://doi.org/10.1200/JCO.2001.19.3.666</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Josephson D., Pasin E. Stein J.P. Superficial bladder cancer: Part 2. Management. Expert Rev. Anticancer Ther. 2007; 7 (4): 567–581. https://doi.org/10.1586/14737140.7.4.567</mixed-citation><mixed-citation xml:lang="en">Josephson D., Pasin E. Stein J.P. Superficial bladder cancer: Part 2. Management. Expert Rev. Anticancer Ther. 2007; 7 (4): 567–581. https://doi.org/10.1586/14737140.7.4.567</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chang S.S., Bochner B.H., Chou R. et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J. Urol. 2017; 198 (3): 552–559. https://doi.org/10.1016/j.juro.2017.04.086</mixed-citation><mixed-citation xml:lang="en">Chang S.S., Bochner B.H., Chou R. et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J. Urol. 2017; 198 (3): 552–559. https://doi.org/10.1016/j.juro.2017.04.086</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kulkarni G.S., Hakenberg O.W., Gschwend J.E. et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur. Urol. 2010; 57 (1): 60–70. https://doi.org/10.1016/j.eururo.2009.08.024</mixed-citation><mixed-citation xml:lang="en">Kulkarni G.S., Hakenberg O.W., Gschwend J.E. et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur. Urol. 2010; 57 (1): 60–70. https://doi.org/10.1016/j.eururo.2009.08.024</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kundra V., Silverman P.M. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. Am. J. Roentgenol. 2003; 180 (4): 1045–1054. https://doi.org/10.2214/ajr.180.4.1801045</mixed-citation><mixed-citation xml:lang="en">Kundra V., Silverman P.M. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. Am. J. Roentgenol. 2003; 180 (4): 1045–1054. https://doi.org/10.2214/ajr.180.4.1801045</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Del Giudice F., Leonardo C., Simone G. et al. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease? BJU Int. 2020; 126 (5): 610–619. https://doi.org/110.1111/bju.15188</mixed-citation><mixed-citation xml:lang="en">Del Giudice F., Leonardo C., Simone G. et al. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease? BJU Int. 2020; 126 (5): 610–619. https://doi.org/110.1111/bju.15188</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu C.Z., Ting H.N., Ng K.H. et al. A review on the accuracy of bladder cancer detection methods. J. Cancer. 2019; 10 (17): 4038–4044. https://doi.org/10.7150/jca.28989</mixed-citation><mixed-citation xml:lang="en">Zhu C.Z., Ting H.N., Ng K.H. et al. A review on the accuracy of bladder cancer detection methods. J. Cancer. 2019; 10 (17): 4038–4044. https://doi.org/10.7150/jca.28989</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">McKibben M.J., Woods M.E. Preoperative imaging for staging bladder cancer. Curr. Urol. Rep. 2015; 16 (4): 22. https://doi.org/10.1007/s11934-015-0496-8</mixed-citation><mixed-citation xml:lang="en">McKibben M.J., Woods M.E. Preoperative imaging for staging bladder cancer. Curr. Urol. Rep. 2015; 16 (4): 22. https://doi.org/10.1007/s11934-015-0496-8</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cathomas R., Lorch A., Bruins H.M. et al. EAU Muscle-invasive, Metastatic Bladder Cancer Guidelines Panel. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur. Urol. 2022; 81 (1): 95–103. https://doi.org/10.1016/j.eururo.2021.09.026</mixed-citation><mixed-citation xml:lang="en">Cathomas R., Lorch A., Bruins H.M. et al. EAU Muscle-invasive, Metastatic Bladder Cancer Guidelines Panel. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur. Urol. 2022; 81 (1): 95–103. https://doi.org/10.1016/j.eururo.2021.09.026</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lin W.C., Chen J.H. Pitfalls and limitations of diffusion-weighted magnetic resonance imaging in the diagnosis of urinary bladder cancer. Transl. Oncol. 2015; 8 (3): 217–230. https://doi.org/10.1016/j.tranon.2015.04.003</mixed-citation><mixed-citation xml:lang="en">Lin W.C., Chen J.H. Pitfalls and limitations of diffusion-weighted magnetic resonance imaging in the diagnosis of urinary bladder cancer. Transl. Oncol. 2015; 8 (3): 217–230. https://doi.org/10.1016/j.tranon.2015.04.003</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ark J.T., Keegan K.A., Barocas D.A. et al. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014; 113 (6): 894–899. https://doi.org/10.1111/bju.12245</mixed-citation><mixed-citation xml:lang="en">Ark J.T., Keegan K.A., Barocas D.A. et al. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014; 113 (6): 894–899. https://doi.org/10.1111/bju.12245</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Huang L., Kong Q., Liu Z. et al. The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology. 2018; 286 (2): 502–511. https://doi.org/10.1148/radiol.2017171028</mixed-citation><mixed-citation xml:lang="en">Huang L., Kong Q., Liu Z. et al. The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology. 2018; 286 (2): 502–511. https://doi.org/10.1148/radiol.2017171028</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gandhi N., Krishna S., Booth C.M. et al. Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. BJU Int. 2018; 122 (5): 744–753. https://doi.org/10.1111/bju.14366.</mixed-citation><mixed-citation xml:lang="en">Gandhi N., Krishna S., Booth C.M. et al. Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. BJU Int. 2018; 122 (5): 744–753. https://doi.org/10.1111/bju.14366.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Panebianco V., Narumi Y., Altun E. et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur. Urol. 2018; 74 (3): 294–306. https://doi.org/10.1016/j.eururo.2018.04.029.</mixed-citation><mixed-citation xml:lang="en">Panebianco V., Narumi Y., Altun E. et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur. Urol. 2018; 74 (3): 294–306. https://doi.org/10.1016/j.eururo.2018.04.029.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Del Giudice F., Barchetti G., De Berardinis E. et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur. Urol. 2020; 77 (1): 101–109. https://doi.org/10.1016/j.eururo.2019.09.029</mixed-citation><mixed-citation xml:lang="en">Del Giudice F., Barchetti G., De Berardinis E. et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur. Urol. 2020; 77 (1): 101–109. https://doi.org/10.1016/j.eururo.2019.09.029</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z., Shang Y., Luan T. et al. Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer. Cancer Imaging. 20, 26 (2020). https://doi.org/10.1186/s40644-020-00304-3</mixed-citation><mixed-citation xml:lang="en">Wang Z., Shang Y., Luan T. et al. Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer. Cancer Imaging. 20, 26 (2020). https://doi.org/10.1186/s40644-020-00304-3</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Woo S., Panebianco V., Narumi Y. et al. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur. Urol. Oncol. 2020; 3 (3): 306–315. https://doi.org/10.1016/j.euo.2020.02.007</mixed-citation><mixed-citation xml:lang="en">Woo S., Panebianco V., Narumi Y. et al. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur. Urol. Oncol. 2020; 3 (3): 306–315. https://doi.org/10.1016/j.euo.2020.02.007</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Luo C., Huang B., Wu Y. et al. Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis. Eur. Radiol. 2020; 30 (8): 4606–4614. https://doi.org/10.1007/s00330-020-06802-z</mixed-citation><mixed-citation xml:lang="en">Luo C., Huang B., Wu Y. et al. Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis. Eur. Radiol. 2020; 30 (8): 4606–4614. https://doi.org/10.1007/s00330-020-06802-z</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Necchi A., Bandini M., Calareso G. et al. Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study. Eur. Urol. 2020; 77 (5): 636–643. https://doi.org/10.1016/j.eururo.2019.12.016</mixed-citation><mixed-citation xml:lang="en">Necchi A., Bandini M., Calareso G. et al. Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study. Eur. Urol. 2020; 77 (5): 636–643. https://doi.org/10.1016/j.eururo.2019.12.016</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Barchetti G., Simone G., Ceravolo I. et al. Multiparametric MRI of the bladder: Inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur. Radiol. 2019; 29: 5498–5506. https://doi.org/10.1007/s00330-019-06117-8</mixed-citation><mixed-citation xml:lang="en">Barchetti G., Simone G., Ceravolo I. et al. Multiparametric MRI of the bladder: Inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur. Radiol. 2019; 29: 5498–5506. https://doi.org/10.1007/s00330-019-06117-8</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Erkoc M., Otunctemur A., Bozkurt M. et al. The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer. Int. J. Clin. Pract. 2021; 75 (9): e14584. https://doi.org/10.1111/ijcp.14584</mixed-citation><mixed-citation xml:lang="en">Erkoc M., Otunctemur A., Bozkurt M. et al. The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer. Int. J. Clin. Pract. 2021; 75 (9): e14584. https://doi.org/10.1111/ijcp.14584</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Del Giudice F., Flammia R.S., Pecoraro M. et al. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. Wld J. Urol. 2022; 40 (7): 1617–1628. https://doi.org/10.1007/s00345-022-03969-6</mixed-citation><mixed-citation xml:lang="en">Del Giudice F., Flammia R.S., Pecoraro M. et al. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. Wld J. Urol. 2022; 40 (7): 1617–1628. https://doi.org/10.1007/s00345-022-03969-6</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Abouelkheir R.T., Abdelhamid A., Abou El-Ghar M. et al. Imaging of Bladder Cancer: Standard Applications and Future Trends. Medicina (Kaunas). 2021; 57 (3): 220. https://doi.org/10.3390/medicina57030220</mixed-citation><mixed-citation xml:lang="en">Abouelkheir R.T., Abdelhamid A., Abou El-Ghar M. et al. Imaging of Bladder Cancer: Standard Applications and Future Trends. Medicina (Kaunas). 2021; 57 (3): 220. https://doi.org/10.3390/medicina57030220</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Stojovska-Jovanovska E., Mitreska N., Stojovski M. et al. Computed tomography or magnetic resonance imaging – our experiences in determining preoperative TNM staging of bladder cancer. Pril (Makedon. Akad. Nauk. Umet. Odd. Med. Nauki). 2013; 34 (3): 63–70.</mixed-citation><mixed-citation xml:lang="en">Stojovska-Jovanovska E., Mitreska N., Stojovski M. et al. Computed tomography or magnetic resonance imaging – our experiences in determining preoperative TNM staging of bladder cancer. Pril (Makedon. Akad. Nauk. Umet. Odd. Med. Nauki). 2013; 34 (3): 63–70.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
